Literature DB >> 33099469

Differential Proteomic Analysis of Hepatocellular Carcinomas from Ppp2r5d Knockout Mice and Normal (Knockout) Livers.

Caroline Lambrecht1, Gabriela Bomfim Ferreira2, Judit DomÈnech Omella1, Louis Libbrecht3, Rita DE Vos4, Rita Derua1, Chantal Mathieu2, Lut Overbergh2, Etienne Waelkens5, Veerle Janssens5,6.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is the major type of primary liver cancer. Mice lacking the tumor-suppressive protein phosphatase 2A subunit B56δ (Ppp2r5d) spontaneously develop HCC, correlating with increased c-MYC oncogenicity.
MATERIALS AND METHODS: We used two-dimensional difference gel electrophoresis-coupled matrix-assisted laser desorption/ionization time-of-flight mass spectrometry to identify differential proteomes of livers from wild-type, non-cancerous and HCC-affected B56δ knockout mice.
RESULTS: A total of 23 proteins were differentially expressed/regulated in liver between wild-type and non-cancerous knockout mice, and 119 between non-cancerous and HCC knockout mice ('cancer proteins'). Overlap with our reported differential transcriptome data was poor. Overall, 56% of cancer proteins were reported before in HCC proteomics studies; 44% were novel. Gene Ontology analysis revealed cancer proteins mainly associated with liver metabolism (18%) and mitochondria (15%). Ingenuity Pathway Analysis identified 'cancer' and 'gastrointestinal disease' as top hits.
CONCLUSION: We identified several proteins for further exploration as novel potential HCC biomarkers, and independently underscored the relevance of Ppp2r5d knockout mice as a valuable hepatocarcinogenesis model. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  2D-DIGE; B56δ subunit; HCC; PP2A; Ppp2r5d; biomarker; fibrinogen; hepatocarcinogenesis; liver; mouse model; proteomics; tumor suppressor

Mesh:

Substances:

Year:  2020        PMID: 33099469      PMCID: PMC7675653          DOI: 10.21873/cgp.20222

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  58 in total

Review 1.  Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.

Authors:  Daniela Sia; Augusto Villanueva; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2016-12-30       Impact factor: 22.682

Review 2.  Molecular therapies and precision medicine for hepatocellular carcinoma.

Authors:  Josep M Llovet; Robert Montal; Daniela Sia; Richard S Finn
Journal:  Nat Rev Clin Oncol       Date:  2018-10       Impact factor: 66.675

3.  Gel-based proteomics of liver cancer progression in rat.

Authors:  Jakob Albrethsen; Leah M Miller; Phyllis M Novikoff; Ruth H Angeletti
Journal:  Biochim Biophys Acta       Date:  2011-06-06

4.  Application of comparative functional genomics to identify best-fit mouse models to study human cancer.

Authors:  Ju-Seog Lee; In-Sun Chu; Arsen Mikaelyan; Diego F Calvisi; Jeonghoon Heo; Janardan K Reddy; Snorri S Thorgeirsson
Journal:  Nat Genet       Date:  2004-11-21       Impact factor: 38.330

Review 5.  Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling.

Authors:  V Janssens; J Goris
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

6.  Protein expression profile characteristic to hepatocellular carcinoma revealed by 2D-DIGE with supervised learning.

Authors:  Reiji Teramoto; Hirotaka Minagawa; Masao Honda; Kenji Miyazaki; Yo Tabuse; Ken'ichi Kamijo; Teruyuki Ueda; Shuichi Kaneko
Journal:  Biochim Biophys Acta       Date:  2008-03-05

7.  Comparative analysis of proteome and transcriptome in human hepatocellular carcinoma using 2D-DIGE and SAGE.

Authors:  Hirotaka Minagawa; Taro Yamashita; Masao Honda; Yo Tabuse; Kenichi Kamijo; Akira Tsugita; Shuichi Kaneko
Journal:  Protein J       Date:  2008-12       Impact factor: 2.371

8.  Loss of protein phosphatase 2A regulatory subunit B56δ promotes spontaneous tumorigenesis in vivo.

Authors:  C Lambrecht; L Libbrecht; X Sagaert; P Pauwels; Y Hoorne; J Crowther; J V Louis; W Sents; A Sablina; V Janssens
Journal:  Oncogene       Date:  2017-10-02       Impact factor: 9.867

9.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.

Authors:  Kornelius Schulze; Sandrine Imbeaud; Eric Letouzé; Ludmil B Alexandrov; Julien Calderaro; Sandra Rebouissou; Gabrielle Couchy; Clément Meiller; Jayendra Shinde; Frederic Soysouvanh; Anna-Line Calatayud; Roser Pinyol; Laura Pelletier; Charles Balabaud; Alexis Laurent; Jean-Frederic Blanc; Vincenzo Mazzaferro; Fabien Calvo; Augusto Villanueva; Jean-Charles Nault; Paulette Bioulac-Sage; Michael R Stratton; Josep M Llovet; Jessica Zucman-Rossi
Journal:  Nat Genet       Date:  2015-03-30       Impact factor: 38.330

Review 10.  Molecular Bases of Drug Resistance in Hepatocellular Carcinoma.

Authors:  Jose J G Marin; Rocio I R Macias; Maria J Monte; Marta R Romero; Maitane Asensio; Anabel Sanchez-Martin; Candela Cives-Losada; Alvaro G Temprano; Ricardo Espinosa-Escudero; Maria Reviejo; Laura H Bohorquez; Oscar Briz
Journal:  Cancers (Basel)       Date:  2020-06-23       Impact factor: 6.639

View more
  1 in total

Review 1.  RNA splicing: a dual-edged sword for hepatocellular carcinoma.

Authors:  Anjali Kashyap; Greesham Tripathi; Avantika Tripathi; Rashmi Rao; Manju Kashyap; Anjali Bhat; Deepak Kumar; Anjali Rajhans; Pravindra Kumar; Darshan Shimoga Chandrashekar; Riaz Mahmood; Amjad Husain; Hatem Zayed; Alok Chandra Bharti; Manoj Kumar Kashyap
Journal:  Med Oncol       Date:  2022-08-16       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.